Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Methodology: The study was an open label, randomized, crossover, 2 periods study in 20 healthy male/female volunteers. Subjects received 500 mg of the new formulation of soluble tablets vigabatrin or Sabril, as single oral administration in 2 different study periods depending on the randomization, with a 7-days wash out period between administrations
Epistemonikos ID: 15b419aaf13e7f5a99c0652a267c209d25294144
First added on: May 07, 2024